In our multicenter study, we studied the distribution of Candida species in vulvovaginal candidiasis patients and investigated antifungal susceptibility profile and genotype of Candida albicans in vaginal swab. A total of 115 Candida albicans strains were detected in 135 clinical isolates. Minimum inhibitory concentration determinations showed that 83% and 81% of the 115 Candida albicans strains were susceptible to fluconazole and voriconazole. Randomly amplified polymorphic DNA analysis (RAPD) was applied to identify clonally related isolates from different patients at the local level. All tested strains were classified into genotype A (77.4%), genotype B (18.3%), and genotype C (4.3%). Genotype A was further classified into five subtypes and genotype B into two subtypes. Candida albicans was the dominant pathogen of vulvovaginal candidiasis, the majority belonging to genotype A in this study. Exposure to azoles is a risk factor for the emergence of azole resistance among Candida albicans isolated from VVC patients.
Introduction
Vulvovaginal candidiasis (VVC) is a common illness attributed to an overgrowth of Candida species, and it has been estimated that 75% of all women will experience an episode of VVC during their lifetime. VVC is the second most common cause of vaginitis after bacterial vaginosis with Candida albicans accounting for between 80-95% of all episodes of VVC worldwide 1, 2 . It is noteworthy that recurrent VVC affects about 5% of all women of childbearing age 3 . More than 20 Candida species have been identified as human pathogens [4] [5] [6] [7] . Research has shown that in majority countries, the most common species detected in patients with VVC were Candida albicans (65-90%), non-albicans species, particularly Candida glabrata, and in rare cases Saccharomyces cerevisiae, which causes less than 10% of all cases of vulvovaginitis, although there was some regional variation. The latter was generally associated with milder clinical symptoms compared to those that present in Candida albicans-associated vaginitis [8] [9] [10] [11] .
394
There is only limited information regarding the antifungal susceptibility and molecular epidemiology of Candida albicans isolates in patients suffering from vulvovaginal candidiasis in China. Despite the small number of samples analyzed, this study contributes to the understanding of the distribution of Candida species in vulvovaginal candidiasis patients and the susceptibility of Candida albicans to the most commonly prescribed systemic antifungal drugs and the molecular relationship and genetic diversity among 115 clinical Candida albicans isolates obtained from patients in three maternity hospitals in the Shanghai region of China. Our data also provides experimental evidence for appropriate clinical monitoring and the correct therapeutic strategy to treat vulvovaginal candidiasis.
Methods

Identification of strains
The present retrospective study collected 135 patients from the Obstetrics and Gynecology Hospital of Fudan University, International Peace Maternity and Child Health Hospital and Shanghai First Maternity and Infant Hospital, between November 2013 and January 2014. These patients presented with VVC and all had a history of at least one prior episode of VVC, occurring from several months to several years prior to this visit. All of these patients had symptoms consistent with VVC, which included vaginal itching, vulval soreness and irritation, pain or discomfort during sexual intercourse, pain or discomfort during urination, white and thick vaginal discharge, pain with sex, and redness around the vagina. The most common symptom in this population was vaginal itching, and some patients had more than one symptom. These patients had all received antifungal treatment for prior VVC. Some patients received fluconazole 150 mg, oral for 7 days. Some received miconazole suppository (200 mg, 7 days), or clotrimazole suppository (150 mg, 7 days). None of the patients visited the clinic routinely. No patients were positive for human immunodeficiency virus. Approval for the research was obtained from the Research Ethics Committee of the three maternity hospitals and written consent was obtained from all patients participated in the study.
All samples were collected by vaginal swab, and only one yeast organism was isolated from each vaginal swab. Swabs were cultured on CHROMagar Candida (ChroMagar, Paris, France) and Yeast Extract Peptone Dextrose Medium (ShengGong, Shanghai, China). All isolates were identified by API 20C AUX (Biomérieux, Lyon, France) 12 .
We collected one isolate per patient.
Antifungal susceptibility testing
Antifungal susceptibility testing for fluconazole and voriconazole was determined by the broth microdilution method using ATB FUNGUS 3 (Biomérieux, France), according to the guidelines outlined in CLSI document M27-S4 [13] [14] . An ATB FUNGUS 3 strip consists of 16 pairs of cupules including two growth control wells and five antifungal drugs at different concentration. A suspension with a turbidity of 2 McFarland was prepared and 20 μl of this suspension was transferred to an ampule of ATB FUNGUS 3 Medium following the manufacturer's instructions and 135 μl of the inoculated medium was transferred into each cupule. After incubation at 35
• C for 24 h, the strips were read visually. According to the manufacturer's instructions, the minimum inhibitory concentrations (MICs) were determined by the growth score for each of the cupules compared with the control cupules.
Quality control strains
Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used as the control strains. Quality control was ensured by testing the CLSI-recommended quality control strains for ATB FUNGUS 3.
RAPD analysis
DNA extraction was carried out by means of the BiospinFungus Genomic DNA Extraction Kit (BioFlux, Shanghai, China). The concentration of nucleic acids was measured using a NanoDrop 2000 ultra-micro spectrophotometer.
The primer was 5 -ACGGCCGACC-3 . Amplification reactions were carried out in an ABI 2700 thermal cycler (Applied Biosystems) with an initial denaturation at 94
• C for (TBE). Gels were stained and photographed 15 . Bands were scored based on presence/absence and not on intensity.
Definition of genomic groups
DNA patterns were compared using the NTsys 2.10e software and the similarity value (S AB ) was calculated for each pair of patterns on the basis of matching fragment positions. The cut-off value of S AB was 0.75 for genetic similarity 16 . The S AB were then clustered by the unweighted pair group method using the arithmetic averages technique and dendrograms were generated to visualize the relationships between isolates.
Data analysis
The χ 2 test was used for proportions in the statistical analysis, performed by means of GraphPad Prism version 5.0 for Windows (GraphPad Software, USA). P < 0.05 was considered a statistically significant difference. 
Results
Strains
Antifungal susceptibility testing
In the present evaluation, ATB visual readings showed good concordance with CLSI microdilution susceptibility testing as described in the literature 17 . According to the guidelines outlined in CLSI document M27S4, of the 115 Candida albicans strains, 95 (83%) were susceptible to fluconazole, and 93 (81%) were susceptible to voriconazole. (Table 1 ). 
RAPD analysis
Discussion
In our study, we found the Candida albicans strain to be the dominant pathogen causing vulvovaginal candidiasis (115, 85%) followed by Candida glabrata (14, 10%), Candida tropicalis (3, 2.2%), Candida parapsilosis (2, 1.5%), and Candida krusei (1, 0.7%), in three institutions in the Shanghai region of China. The susceptibility rate of Candida albicans to fluconazole and voriconazole was about 80% and the 115 Candida albicans were classified into three genotypes: genotype A (77.4%), genotype B (18.3%), and genotype C (4.3%). Recently, researchers also reported that Candida albicans is the most common cause of vaginitis. In southern China, the most common pathogens causing vulvovaginal candidiasis reportedly were Candida albicans (91.4%), Candida glabrata (4.3%), Candida tropicalis (3.2%), and Candida parapsilosis (1.1%) 18 . In Argentina, the most Table 1 . Susceptibility rates of Candida albicans to the fungal drugs tested. 20 .
In vitro antifungal susceptibility testing of Candida albicans is important to establish the susceptibility patterns of isolates recovered from different regions and countries to detect the prevalence of resistant isolates 21 . 23 . In our study, the susceptibility rates of Candida albicans to fluconazole and voriconazole were about 80%. A 20% nonsusceptible rate to fluconazole and voriconazole may be because these 135 patients have a history of VVC, and the 7% resistant to fluconazole were collected from patients who had received prior fluconazole. The increased use of over-the-counter antifungals and prolonged therapy are risk factors for the emergence of azole resistance among C. albicans isolated from VVC patients. Recent exposure to azoles has been noted by others as an important risk factor for bloodstream infection with fluconazole-resistant Candida spp 24 .
An investigation of the genetic relatedness between clinical Candida strains may be of great importance in the clinical diagnosis, epidemiology, treatment, and prevention of candidiasis. Molecular methods of studying strain relatedness have proven to be quite useful, allowing investigators to examine, retrospectively, putative outbreaks of candidiasis and assess epidemiological aspects of these outbreaks. RAPD analyses are used as tools useful in tracing the routes of transmission of different microorganisms, including Candida species 25 .
In the present study, no significant differences were detected between the RAPD types in the three maternity hospitals. The majority of molecular typing was genotype A with genotype C only being isolated from patients in Obstetrics and Gynecology Hospital of Fudan University, Thus, unequivocally the genotype of Candida albicans in vaginal isolates from these institutions in Shanghai is mainly type A, although the RAPD technique raises the problem of reproducibility and data comparison between laboratories. This technique is still used to investigate Candida albicans epidemiology at the local level 26 .
In conclusion, our study has shown that Candida albicans is the dominant pathogen of vulvovaginal candidiasis, and the increased use of azole antifungals may be an important risk factor for the emergence of azole resistance among C. albicans isolated from VVC patients. Molecular typing revealed that genotype A is predominant in this study. Our results provide experimental evidence for clinical application of azole agents and molecular epidemiology monitoring.
